HELEN OF TROY LTD — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HELEN OF TROY LTD filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Feb 28, 2018 | $1.48B | Apr 29, 2020 |
| FY2019 | Feb 28, 2017 | $1.40B | Apr 29, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $1.91B | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $2.01B | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $2.07B | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | $2.22B | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | $2.10B | Apr 27, 2023 |
| FY2020 | Feb 29, 2020 | $442.37M | Apr 29, 2020 |
| FY2020 | Nov 30, 2019 | $474.74M | Apr 29, 2020 |
| FY2020 | Aug 31, 2019 | $414.00M | Apr 29, 2020 |
| FY2020 | May 31, 2019 | $376.34M | Apr 29, 2020 |
| FY2020 | Feb 28, 2019 | $384.84M | Apr 29, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Feb 28, 2018 | $390.85M | Apr 30, 2018 |
| FY2018 | Nov 30, 2017 | $423.71M | Apr 30, 2018 |
| FY2018 | Aug 31, 2017 | $347.21M | Apr 30, 2018 |
| FY2018 | May 31, 2017 | $327.99M | Apr 30, 2018 |
| FY2018 | Feb 28, 2017 | $347.37M | Apr 30, 2018 |
| FY2018 | Nov 30, 2016 | $412.25M | Apr 30, 2018 |
| FY2018 | Aug 31, 2016 | $335.06M | Apr 30, 2018 |
| FY2018 | May 31, 2016 | $312.00M | Apr 30, 2018 |
| FY2017 | Feb 29, 2016 | $385.72M | May 1, 2017 |
| FY2017 | Nov 30, 2015 | $445.50M | May 1, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $914.41M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $948.66M | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $899.35M | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | $953.19M | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | $927.30M | Apr 27, 2023 |
| FY2020 | Feb 29, 2020 | $192.62M | Apr 29, 2020 |
| FY2020 | Nov 30, 2019 | $209.97M | Apr 29, 2020 |
| FY2020 | Aug 31, 2019 | $178.15M | Apr 29, 2020 |
| FY2020 | May 31, 2019 | $153.73M | Apr 29, 2020 |
| FY2020 | Feb 28, 2019 | $157.53M | Apr 29, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $123.75M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $168.59M | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $143.27M | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | $223.76M | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | $253.95M | Apr 27, 2023 |
| FY2022 | Feb 29, 2020 | $152.33M | Apr 28, 2022 |
| FY2021 | Feb 28, 2019 | $168.55M | Apr 29, 2021 |
| FY2020 | Feb 28, 2018 | $44.45M | Apr 29, 2020 |
| FY2019 | Feb 28, 2017 | $140.69M | Apr 29, 2019 |
| FY2018 | Feb 29, 2016 | $101.23M | Apr 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $142.75M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $260.59M | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $211.79M | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | $272.55M | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | $281.49M | Apr 27, 2023 |
| FY2022 | Feb 29, 2020 | $178.25M | Apr 28, 2022 |
| FY2021 | Feb 28, 2019 | $199.38M | Apr 29, 2021 |
| FY2020 | Feb 28, 2018 | $169.06M | Apr 29, 2020 |
| FY2019 | Feb 28, 2017 | $169.66M | Apr 29, 2019 |
| FY2018 | Feb 29, 2016 | $116.29M | Apr 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $53.90M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $56.50M | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $47.80M | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | $54.00M | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | $53.40M | Apr 27, 2023 |
| FY2022 | Feb 29, 2020 | $17.80M | Apr 28, 2022 |
| FY2021 | Feb 28, 2019 | $13.00M | Apr 29, 2021 |
| FY2020 | Feb 28, 2018 | $13.50M | Apr 29, 2020 |
| FY2019 | Feb 28, 2017 | $11.80M | Apr 29, 2019 |
| FY2018 | Feb 29, 2016 | $11.60M | Apr 30, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $705.38M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $669.36M | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $660.20M | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | $680.26M | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | $637.01M | Apr 27, 2023 |
| FY2022 | Feb 29, 2020 | $511.90M | Apr 28, 2022 |
| FY2021 | Feb 28, 2019 | $438.14M | Apr 29, 2021 |
| FY2020 | Feb 28, 2018 | $424.83M | Apr 29, 2020 |
| FY2019 | Feb 28, 2017 | $400.85M | Apr 29, 2019 |
| FY2018 | Feb 29, 2016 | $403.44M | Apr 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $113.21M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $306.07M | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $208.24M | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | $140.82M | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | $314.11M | Apr 27, 2023 |
| FY2022 | Feb 29, 2020 | $271.29M | Apr 28, 2022 |
| FY2021 | Feb 28, 2019 | $195.30M | Apr 29, 2021 |
| FY2020 | Feb 28, 2018 | $224.21M | Apr 29, 2020 |
| FY2019 | Feb 28, 2017 | $228.50M | Apr 29, 2019 |
| FY2018 | Feb 29, 2016 | $186.55M | Apr 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $3.13B | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $2.84B | Apr 24, 2025 |
| FY2024 | Feb 28, 2023 | $2.91B | Apr 24, 2024 |
| FY2023 | Feb 28, 2022 | $2.82B | Apr 27, 2023 |
| FY2022 | Feb 28, 2021 | $2.26B | Apr 28, 2022 |
| FY2021 | Feb 29, 2020 | $1.90B | Apr 29, 2021 |
| FY2020 | Feb 28, 2019 | $1.65B | Apr 29, 2020 |
| FY2019 | Feb 28, 2018 | $1.62B | Apr 29, 2019 |
| FY2018 | Feb 28, 2017 | $1.81B | Apr 30, 2018 |
| FY2018 | Feb 29, 2016 | $1.63B | Apr 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $1.45B | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $1.20B | Apr 24, 2025 |
| FY2024 | Feb 28, 2023 | $1.42B | Apr 24, 2024 |
| FY2023 | Feb 28, 2022 | $1.50B | Apr 27, 2023 |
| FY2022 | Feb 28, 2021 | $1.02B | Apr 28, 2022 |
| FY2021 | Feb 29, 2020 | $742.16M | Apr 29, 2021 |
| FY2020 | Feb 28, 2019 | $652.90M | Apr 29, 2020 |
| FY2019 | Feb 28, 2018 | $609.26M | Apr 29, 2019 |
| FY2018 | Feb 28, 2017 | $792.33M | Apr 30, 2018 |
| FY2017 | Feb 29, 2016 | $918.85M | May 1, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $1.68B | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $1.64B | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | $1.49B | Apr 24, 2025 |
| FY2025 | Feb 28, 2022 | $1.33B | Apr 24, 2025 |
| FY2024 | Feb 28, 2021 | $1.24B | Apr 24, 2024 |
| FY2023 | Feb 29, 2020 | $1.16B | Apr 27, 2023 |
| FY2022 | Feb 28, 2019 | $996.64M | Apr 28, 2022 |
| FY2021 | Feb 28, 2018 | $1.01B | Apr 29, 2021 |
| FY2020 | Feb 28, 2017 | $1.02B | Apr 29, 2020 |
| FY2019 | Feb 29, 2016 | $930.04M | Apr 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $1.18B | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $1.07B | Apr 24, 2025 |
| FY2024 | Feb 28, 2023 | $1.07B | Apr 24, 2024 |
| FY2023 | Feb 28, 2022 | $948.87M | Apr 27, 2023 |
| FY2022 | Feb 28, 2021 | $739.90M | Apr 28, 2022 |
| FY2021 | Feb 29, 2020 | $739.90M | Apr 29, 2021 |
| FY2020 | Feb 28, 2019 | $602.32M | Apr 29, 2020 |
| FY2019 | Feb 28, 2018 | $602.32M | Apr 29, 2019 |
| FY2018 | Feb 28, 2017 | $602.32M | Apr 30, 2018 |
| FY2017 | Feb 29, 2016 | $583.01M | May 1, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $1.31B | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $1.28B | Apr 24, 2025 |
| FY2024 | Feb 28, 2023 | $1.16B | Apr 24, 2024 |
| FY2023 | Feb 28, 2022 | $1.02B | Apr 27, 2023 |
| FY2022 | Feb 28, 2021 | $965.17M | Apr 28, 2022 |
| FY2021 | Feb 29, 2020 | $898.17M | Apr 29, 2021 |
| FY2020 | Feb 28, 2019 | $746.37M | Apr 29, 2020 |
| FY2019 | Feb 28, 2018 | $780.49M | Apr 29, 2019 |
| FY2018 | Feb 28, 2017 | $798.13M | Apr 30, 2018 |
| FY2017 | Feb 29, 2016 | $728.53M | May 1, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $18.87M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | $18.50M | Apr 24, 2025 |
| FY2024 | Feb 28, 2023 | $29.07M | Apr 24, 2024 |
| FY2023 | Feb 28, 2022 | $33.38M | Apr 27, 2023 |
| FY2022 | Feb 28, 2021 | $45.12M | Apr 28, 2022 |
| FY2021 | Feb 29, 2020 | $24.47M | Apr 29, 2021 |
| FY2020 | Feb 28, 2019 | $11.87M | Apr 29, 2020 |
| FY2019 | Feb 28, 2018 | $20.74M | Apr 29, 2019 |
| FY2018 | Feb 28, 2017 | $23.85M | Apr 30, 2018 |
| FY2018 | Feb 29, 2016 | $227.46M | Apr 30, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $921.85M | Apr 24, 2025 |
| FY2024 | Feb 29, 2024 | $671.95M | Apr 24, 2024 |
| FY2023 | Feb 28, 2023 | $936.88M | Apr 27, 2023 |
| FY2022 | Feb 28, 2022 | $816.21M | Apr 28, 2022 |
| FY2021 | Feb 28, 2021 | $347.61M | Apr 29, 2021 |
| FY2020 | Feb 29, 2020 | $339.31M | Apr 29, 2020 |
| FY2020 | Feb 28, 2019 | $320.78M | Apr 29, 2020 |
| FY2019 | Feb 28, 2018 | $289.87M | Apr 29, 2019 |
| FY2018 | Feb 28, 2017 | $485.62M | Apr 30, 2018 |
| FY2017 | Feb 29, 2016 | $619.91M | May 1, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 5 | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | 7 | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | 5 | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | 9 | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | 10 | Apr 27, 2023 |
| FY2020 | Feb 29, 2020 | 0 | Apr 29, 2020 |
| FY2020 | Nov 30, 2019 | 2 | Apr 29, 2020 |
| FY2020 | Aug 31, 2019 | 1 | Apr 29, 2020 |
| FY2020 | May 31, 2019 | 1 | Apr 29, 2020 |
| FY2020 | Feb 28, 2019 | 1 | Apr 29, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 5 | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | 7 | Apr 24, 2025 |
| FY2025 | Feb 28, 2023 | 5 | Apr 24, 2025 |
| FY2024 | Feb 28, 2022 | 9 | Apr 24, 2024 |
| FY2023 | Feb 28, 2021 | 10 | Apr 27, 2023 |
| FY2020 | Feb 29, 2020 | 0 | Apr 29, 2020 |
| FY2020 | Nov 30, 2019 | 2 | Apr 29, 2020 |
| FY2020 | Aug 31, 2019 | 1 | Apr 29, 2020 |
| FY2020 | May 31, 2019 | 1 | Apr 29, 2020 |
| FY2020 | Feb 28, 2019 | 1 | Apr 29, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 22.86M | Apr 24, 2025 |
| FY2025 | Feb 29, 2024 | 23.75M | Apr 24, 2025 |
| FY2024 | Feb 28, 2023 | 23.99M | Apr 24, 2024 |
| FY2023 | Feb 28, 2022 | 23.80M | Apr 27, 2023 |
| FY2022 | Feb 28, 2021 | 24.41M | Apr 28, 2022 |
| FY2021 | Feb 29, 2020 | 25.19M | Apr 29, 2021 |
| FY2020 | Feb 28, 2019 | 24.95M | Apr 29, 2020 |
| FY2019 | Feb 28, 2018 | 26.58M | Apr 29, 2019 |
| FY2018 | Feb 28, 2017 | 27.03M | Apr 30, 2018 |
| FY2017 | Feb 29, 2016 | 27.74M | May 1, 2017 |